Shares of NeuroOne Medical Technologies Corporation (NASDAQ:NMTC – Get Free Report) have earned an average recommendation of “Hold” from the five ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $11.6667.
Several research firms have commented on NMTC. Weiss Ratings lowered shares of NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. JonesTrading began coverage on shares of NeuroOne Medical Technologies in a report on Monday, March 2nd. They issued a “buy” rating and a $9.00 target price on the stock. Wall Street Zen raised shares of NeuroOne Medical Technologies to a “sell” rating in a report on Saturday, February 21st. Zacks Research lowered shares of NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a report on Friday, March 13th. Finally, LADENBURG THALM/SH SH raised their target price on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a “buy” rating in a report on Wednesday.
Check Out Our Latest Stock Analysis on NeuroOne Medical Technologies
NeuroOne Medical Technologies Stock Performance
NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). NeuroOne Medical Technologies had a negative return on equity of 98.33% and a negative net margin of 68.35%.The business had revenue of $2.39 million for the quarter, compared to the consensus estimate of $2.58 million. Sell-side analysts anticipate that NeuroOne Medical Technologies will post -0.35 EPS for the current year.
Insider Buying and Selling
In other news, insider David J. Wambeke bought 166,666 shares of the firm’s stock in a transaction on Sunday, March 1st. The shares were purchased at an average cost of $4.02 per share, with a total value of $669,997.32. Following the acquisition, the insider directly owned 166,666 shares in the company, valued at $669,997.32. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders have sold 2,438 shares of company stock valued at $11,702. 11.80% of the stock is owned by company insiders.
Hedge Funds Weigh In On NeuroOne Medical Technologies
Several hedge funds have recently bought and sold shares of NMTC. Legato Capital Management LLC acquired a new position in shares of NeuroOne Medical Technologies in the 4th quarter worth approximately $34,000. Squarepoint Ops LLC acquired a new position in shares of NeuroOne Medical Technologies in the 4th quarter worth approximately $36,000. Susquehanna International Group LLP acquired a new position in shares of NeuroOne Medical Technologies in the 3rd quarter worth approximately $47,000. XTX Topco Ltd acquired a new position in shares of NeuroOne Medical Technologies in the 2nd quarter worth approximately $51,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of NeuroOne Medical Technologies in the 1st quarter valued at $84,000. 16.07% of the stock is owned by institutional investors.
About NeuroOne Medical Technologies
NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.
The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.
Read More
- Five stocks we like better than NeuroOne Medical Technologies
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for NeuroOne Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroOne Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
